Ironwood Pharmaceuticals, Inc.
Index- P/E3.55 EPS (ttm)3.23 Insider Own1.60% Shs Outstand155.69M Perf Week-2.30%
Market Cap1.78B Forward P/E7.74 EPS next Y1.48 Insider Trans-10.38% Shs Float145.93M Perf Month-4.74%
Income528.40M PEG- EPS next Q0.32 Inst Own- Short Float11.21% Perf Quarter8.01%
Sales413.80M P/S4.31 EPS this Y386.30% Inst Trans-0.16% Short Ratio6.69 Perf Half Y-5.83%
Book/sh3.55 P/B3.23 EPS next Y12.98% ROA- Target Price13.00 Perf Year-7.80%
Cash/sh3.81 P/C3.01 EPS next 5Y- ROE- 52W Range10.13 - 14.27 Perf YTD-1.72%
Dividend- P/FCF- EPS past 5Y50.40% ROI52.80% 52W High-19.55% Beta1.15
Dividend %- Quick Ratio4.80 Sales past 5Y8.60% Gross Margin- 52W Low13.33% ATR0.42
Employees219 Current Ratio4.80 Sales Q/Q9.80% Oper. Margin59.10% RSI (14)41.89 Volatility3.57% 3.52%
OptionableYes Debt/Eq1.00 EPS Q/Q62.20% Profit Margin- Rel Volume0.22 Prev Close11.46
ShortableYes LT Debt/Eq0.76 EarningsMay 05 BMO Payout0.00% Avg Volume2.44M Price11.48
Recom2.40 SMA20-3.08% SMA50-5.40% SMA200-5.31% Volume39,132 Change0.17%
Apr-22-22Initiated Piper Sandler Overweight $16
Sep-30-20Downgrade Wells Fargo Overweight → Equal Weight $14 → $9
Jun-17-20Initiated Northland Capital Outperform $14
Jul-10-19Resumed Credit Suisse Neutral
Mar-27-19Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-19Upgrade H.C. Wainwright Sell → Neutral $14
Jan-24-19Upgrade JP Morgan Underweight → Neutral
Nov-07-18Downgrade JP Morgan Neutral → Underweight
Nov-07-18Downgrade Credit Suisse Outperform → Neutral
Jul-23-18Initiated H.C. Wainwright Sell $12.50
May-09-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-05-18Downgrade BofA/Merrill Buy → Underperform
Dec-06-17Downgrade Mizuho Buy → Neutral $16
Jul-21-17Downgrade JP Morgan Overweight → Neutral
May-03-17Initiated Wells Fargo Outperform
Apr-07-17Reiterated Mizuho Buy $21 → $22
Feb-22-17Reiterated Barclays Equal Weight $13 → $16
Nov-04-16Reiterated Mizuho Buy $19 → $20
Oct-24-16Reiterated Wedbush Neutral $10 → $13
Oct-10-16Reiterated Mizuho Buy $24 → $19
May-09-22 08:00AM  
May-06-22 10:24AM  
May-05-22 08:45AM  
Apr-28-22 03:02PM  
Apr-21-22 04:01PM  
Apr-14-22 05:35AM  
Mar-17-22 10:45AM  
Mar-02-22 07:30AM  
Feb-18-22 10:54AM  
Feb-17-22 07:00AM  
Feb-16-22 09:11AM  
Feb-15-22 10:14AM  
Feb-10-22 09:35AM  
Feb-03-22 07:30AM  
Jan-21-22 05:38PM  
Jan-10-22 07:20AM  
Jan-05-22 07:30AM  
Dec-24-21 06:38AM  
Dec-23-21 11:15PM  
Dec-11-21 03:16PM  
Dec-01-21 07:30AM  
Nov-05-21 10:35AM  
Nov-04-21 02:01PM  
Oct-25-21 07:30AM  
Oct-21-21 07:00AM  
Oct-18-21 04:04AM  
Oct-05-21 12:47PM  
Oct-04-21 01:00AM  
Oct-01-21 10:13AM  
Sep-08-21 11:34AM  
Sep-03-21 10:10AM  
Sep-02-21 07:30AM  
Aug-26-21 11:04AM  
Aug-06-21 11:52AM  
Aug-05-21 04:01PM  
Aug-04-21 12:10PM  
Aug-03-21 07:30AM  
Jul-29-21 03:05PM  
Jul-23-21 04:47PM  
Jul-22-21 04:01PM  
Jul-21-21 03:25AM  
Jul-12-21 03:39PM  
Jun-16-21 07:45AM  
Jun-15-21 03:52AM  
Jun-07-21 04:01PM  
May-26-21 04:01PM  
May-24-21 08:00AM  
May-17-21 08:30AM  
May-12-21 10:03AM  
May-10-21 06:16AM  
May-07-21 10:47AM  
May-06-21 02:01PM  
May-05-21 11:54AM  
May-03-21 12:02PM  
Apr-30-21 08:03AM  
Apr-29-21 05:04PM  
Apr-22-21 04:01PM  
Apr-20-21 10:13AM  
Apr-15-21 04:46AM  
Mar-19-21 11:30AM  
Mar-01-21 06:40AM  
Feb-27-21 06:15AM  
Feb-19-21 04:01PM  
Feb-17-21 12:00PM  
Feb-10-21 12:31PM  
Feb-09-21 08:09AM  
Feb-08-21 04:01PM  
Feb-03-21 04:01PM  
Jan-05-21 07:30AM  
Dec-05-20 11:32AM  
Dec-04-20 08:44AM  
Dec-03-20 08:30AM  
Nov-30-20 01:39PM  
Nov-27-20 12:20PM  
Nov-07-20 12:31AM  
Nov-06-20 04:01PM  
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Silver RonaldPrincipal Accounting OfficerMar 24Sale12.753,03138,645105,193Mar 25 04:07 PM
McHugh JulieDirectorMar 14Sale11.6720,000233,400118,373Mar 16 04:05 PM
Silver RonaldPrincipal Accounting OfficerFeb 28Sale10.772,23824,10361,211Mar 02 04:01 PM
Rickard JasonSVP, Chief Operating OfficerFeb 28Sale10.7728,962311,921327,113Mar 02 04:00 PM
Shetzline MichaelCMO,SVP,Head-Res&DrugFeb 28Sale10.7717,607189,627195,380Mar 02 04:01 PM
MCCOURT Thomas AChief Executive OfficerFeb 28Sale10.7748,424521,526586,320Mar 02 04:01 PM
MCCOURT Thomas AChief Executive OfficerDec 22Sale11.4146,327528,591574,454Dec 23 04:18 PM
Rickard JasonSVP, Chief Operating OfficerDec 16Sale11.2827,000304,560319,901Dec 20 04:08 PM
McHugh JulieDirectorDec 14Sale11.0210,000110,200138,373Dec 16 04:06 PM
MCCOURT Thomas AChief Executive OfficerNov 23Sale11.5852,644609,618618,545Nov 24 04:09 PM
Shetzline MichaelCMO,SVP,Head-Res&DrugNov 23Sale11.5813,776159,526183,661Nov 24 04:08 PM
Rickard JasonSVP, Chief Operating OfficerNov 23Sale11.5817,193199,095344,665Nov 24 04:09 PM
Silver RonaldPrincipal Accounting OfficerNov 23Sale11.581,46216,93061,213Nov 24 04:07 PM
Silver RonaldPrincipal Accounting OfficerAug 16Sale13.485677,64362,675Aug 18 04:06 PM
Rickard JasonSVP, Chief Operating OfficerAug 16Sale13.486809,166361,858Aug 18 04:03 PM
Currie Mark GDirectorJun 14Sale11.5923,571273,188570,187Jun 16 04:10 PM
MCCOURT Thomas APresident and Interim CEOMay 24Sale12.251,71621,021566,499May 26 04:01 PM
Shetzline MichaelCMO, SVP & Head of Drug Devt.May 24Sale12.252,07725,443197,437May 26 04:05 PM
Rickard JasonSVP, Chief Operating OfficerMay 24Sale12.255166,321362,538May 26 04:03 PM